- ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
- ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
- ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
- ALX Oncology Appoints Allison Dillon as Chief Business Officer
- ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
- ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
- ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
- ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Monday, ALX Oncology Holdings Inc (ALXO:NSQ) closed at 8.67, 120.29% above the 52 week low of 3.94 set on Aug 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.86 |
---|---|
High | 8.98 |
Low | 8.55 |
Bid | 8.50 |
Offer | 9.04 |
Previous close | 9.01 |
Average volume | 1.53m |
---|---|
Shares outstanding | 52.10m |
Free float | 41.34m |
P/E (TTM) | -- |
Market cap | 483.49m USD |
EPS (TTM) | -3.71 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 21:00 BST.
More ▼